CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus.

Taubmann J, Müller F, Mutlu MY, Völkl S, Aigner M, Bozec A, Mackensen A, Grieshaber Bouyer R, Schett G (2024)

Publication Type: Journal article, Review article

Publication year: 2024

Journal

Arthritis and Rheumatology Wiley

Book Volume: 76

Pages Range: 497-504

Journal Issue: 4

DOI: 10.1002/art.42784

Abstract

B cell generation of autoantibodies is a crucial step in the pathogenesis of systemic lupus erythematosus (SLE). After their differentiation in the bone marrow, B cells populate the secondary lymphatic organs, where they undergo further maturation leading to the development of memory B cells as well as antibody-producing plasmablasts and plasma cells. Targeting B cells is an important strategy to treat autoimmune diseases such as SLE, in which B cell tolerance is disturbed and autoimmune B cells and autoantibodies emerge. This review discusses the functional aspects of antibody- and cell-based B cell-depleting therapy in SLE. It thereby particularly focuses on lessons learned from chimeric antigen receptor (CAR) T cell treatment on the role of B cells in SLE for understanding B cell pathology in SLE. CAR T cells model a deep B cell depletion and thereby allow understanding the role of aberrant B cell activation in the pathogenesis of SLE. Furthermore, the effects of B cell depletion on autoantibody production can be better described, ie, explaining the concept of different cellular sources of (auto-) antibodies in the form of short-lived plasmablasts and long-lived plasma cells, which differ in their susceptibility to B cell depletion and require different targeted therapeutic approaches. Finally, the safety of deep B cell depletion in autoimmune disease is discussed.

Authors with CRIS profile

Jule Taubmann Department of Medicine 3 – Rheumatology and Immunology Fabian Müller Department of Medicine 5 – Haematology and Oncology Simon Völkl Department of Medicine 5 – Haematology and Oncology Aline Bozec Professur für Experimentelle Immuntherapie Andreas Mackensen Lehrstuhl für Innere Medizin V Ricardo Grieshaber Bouyer Professur für Klinische Systemimmunologie Georg Schett Lehrstuhl für Innere Medizin III

How to cite

APA:

Taubmann, J., Müller, F., Mutlu, M.Y., Völkl, S., Aigner, M., Bozec, A.,... Schett, G. (2024). CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 76(4), 497-504. https://doi.org/10.1002/art.42784

MLA:

Taubmann, Jule, et al. "CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus." Arthritis and Rheumatology 76.4 (2024): 497-504.

BibTeX: Download